Harm methotrexate. Medical search. Frequent questions

Home page Questions and answers Statistics Donations Contact

Diseases18

Arthritis, Rheumatoid Leukemia L1210 Precursor Cell Lymphoblastic Leukemia-Lymphoma Pregnancy, Ectopic Osteosarcoma Leukemia, Lymphoid Central Nervous System Neoplasms Pregnancy, Tubal Sarcoma 180 Psoriasis Gestational Trophoblastic Disease Mucositis Carcinoma, Ehrlich Tumor Arthritis, Juvenile Arthritis, Psoriatic Trophoblastic Neoplasms Breast Neoplasms Leukemia L5178

Chemicals and Drugs40

Methotrexate Polyglutamic Acid Antirheumatic Agents Folic Acid Antagonists Tetrahydrofolate Dehydrogenase Aminopterin Antimetabolites, Antineoplastic Reduced Folate Carrier Protein Trimetrexate Folic Acid gamma-Glutamyl Hydrolase Leucovorin Tetrahydrofolates Abortifacient Agents, Nonsteroidal Cyclophosphamide Immunosuppressive Agents Sulfasalazine Vincristine Deoxyuridine 6-Mercaptopurine Dermatologic Agents Fluorouracil Formyltetrahydrofolates Folate Receptors, GPI-Anchored Doxorubicin Phosphoribosylaminoimidazolecarboxamide Formyltransferase Prednisone Cytarabine Thymidylate Synthase Hydroxychloroquine Pteroylpolyglutamic Acids Isoxazoles Asparaginase Hydroxymethyl and Formyl Transferases Probenecid Nucleotide Deaminases Vinblastine Antibodies, Monoclonal Cisplatin Hypoxanthines

Analytical, Diagnostic and Therapeutic Techniques and Equipment11

Drug Therapy, Combination Treatment Outcome Antineoplastic Combined Chemotherapy Protocols Drug Administration Schedule Injections, Spinal Remission Induction Double-Blind Method Combined Modality Therapy Administration, Oral Severity of Illness Index Survival Analysis

Psychiatry and Psychology2

Harm Reduction Self-Injurious Behavior

Phenomena and Processes4

Drug Resistance Dose-Response Relationship, Drug Biological Transport Time Factors

Health Care4

Treatment Outcome Double-Blind Method Severity of Illness Index Survival Analysis

Diseases Chemicals and Drugs Analytical, Diagnostic and Therapeutic Techniques and Equipment Psychiatry and Psychology Phenomena and Processes Health Care

Methotrexate Harm Reduction Polyglutamic Acid Antirheumatic Agents Folic Acid Antagonists Tetrahydrofolate Dehydrogenase Arthritis, Rheumatoid Aminopterin Antimetabolites, Antineoplastic Leukemia L1210 Reduced Folate Carrier Protein Trimetrexate Folic Acid Drug Therapy, Combination gamma-Glutamyl Hydrolase Leucovorin Tetrahydrofolates Treatment Outcome Abortifacient Agents, Nonsteroidal Cyclophosphamide Drug Resistance Antineoplastic Combined Chemotherapy Protocols Immunosuppressive Agents Sulfasalazine Drug Administration Schedule Vincristine Deoxyuridine Precursor Cell Lymphoblastic Leukemia-Lymphoma 6-Mercaptopurine Dermatologic Agents Pregnancy, Ectopic Fluorouracil Formyltetrahydrofolates Folate Receptors, GPI-Anchored Doxorubicin Phosphoribosylaminoimidazolecarboxamide Formyltransferase Dose-Response Relationship, Drug Osteosarcoma Injections, Spinal Prednisone Cytarabine Thymidylate Synthase Leukemia, Lymphoid Hydroxychloroquine Central Nervous System Neoplasms Pregnancy, Tubal Sarcoma 180 Pteroylpolyglutamic Acids Isoxazoles Psoriasis Asparaginase Gestational Trophoblastic Disease Remission Induction Biological Transport Hydroxymethyl and Formyl Transferases Probenecid Time Factors Mucositis Double-Blind Method Nucleotide Deaminases Carcinoma, Ehrlich Tumor Combined Modality Therapy Vinblastine Antibodies, Monoclonal Arthritis, Juvenile Arthritis, Psoriatic Administration, Oral Self-Injurious Behavior Trophoblastic Neoplasms Breast Neoplasms Leukemia L5178 Severity of Illness Index Cisplatin Survival Analysis Hypoxanthines

No FAQ available that match "harm methotrexate"